Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06795022 · ClinicalTrials.gov registry record · Phase 1

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

A Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
304
Enrollment target
20
Study locations

NCT06795022 is a Phase 1 study of Hepatocellular Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 304 participants, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06795022, a Phase 1 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
304 participants
Enrollment target
20
Study locations

Study Summary

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG AZD9793 Intravenous (IV) monotherapy
  • DRUG AZD9793 Subcutaneous (SC) monotherapy)

Study Locations (20)

Other

  • Research Site - Chengdu
  • Research Site - Guangzhou
  • Research Site - Harbin
  • Research Site - Shanghai
  • Research Site - Pokfulam
  • Research Site - Shatin
  • Research Site - Kashiwa
  • Research Site - Yokohama
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Barcelona
  • Research Site - Pamplona
  • Research Site - Taipei
  • Research Site - Taoyuan District

California

  • Research Site - La Jolla
  • Research Site - Los Angeles

Maryland

  • Research Site - Baltimore

Missouri

  • Research Site - St Louis

New Jersey

  • Research Site - Hackensack

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 304 participants
Start Date 2025-03-27
Est. Completion 2028-07-25
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06795022

The ClinicalTrials.gov registry entry for NCT06795022 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (19% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which AZD9793 Intravenous (IV) monotherapy is the first listed.

NCT06795022 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT06795022 about?

NCT06795022 is a clinical study titled "First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours". This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

What is the current status of trial NCT06795022?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 304 participants. The study started on 2025-03-27. Estimated completion is 2028-07-25.

What conditions does trial NCT06795022 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT06795022?

The interventions under investigation include: AZD9793 Intravenous (IV) monotherapy (DRUG), AZD9793 Subcutaneous (SC) monotherapy) (DRUG).

Who is sponsoring clinical trial NCT06795022?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06795022 being conducted?

This trial has 20 study locations across California, Maryland, Missouri, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.